XML 21 R11.htm IDEA: XBRL DOCUMENT v3.21.2
Revenue from Contracts with Customers
 6 Months Ended
Jun. 30, 2021
Revenue from Contract with Customer [Abstract]  
Revenue from Contracts with Customers Revenue from Contracts with Customers
The following table summarizes revenue by revenue source as follows:
Three Months Ended
June 30,		Six Months Ended
June 30,
Major Products/Service Lines (in thousands)2021202020212020
    Product revenue, net(1)

$93,562 $64,927 $180,881 $155,140 
    License and royalty revenues7,502 1,083 12,692 1,574 
Total revenues$101,064 $66,010 $193,573 $156,714 
________________________________
(1)The Company’s principal products include DEFINITY and TechneLite and are categorized within product revenue, net. The Company applies the
same revenue recognition policies and judgments for all its principal products.
The Company classifies its revenues into three product categories: precision diagnostics, radiopharmaceutical oncology, and strategic partnerships and other. Precision diagnostics includes DEFINITY, TechneLite and other imaging diagnostic products. Radiopharmaceutical oncology consists primarily of AZEDRA and PYLARIFY. Strategic partnerships and other includes partnerships related to other products, such as RELISTOR, that improve patient outcomes and care.
Revenue by product category on a net basis is as follows:
Three Months Ended
June 30,		Six Months Ended
June 30,
(in thousands)2021
2020(1)
2021
2020(1)
   DEFINITY$59,842 $37,125 $115,813 $89,630 
   TechneLite23,772 18,668 46,572 41,447 
   Other precision diagnostics6,742 7,140 13,726 20,197 
Total precision diagnostics90,356 62,933 176,111 151,274 
Radiopharmaceutical oncology2,812 2,183 4,312 4,151 
Strategic partnerships and other7,896 894 13,150 1,289 
   Total revenues$101,064 $66,010 $193,573 $156,714 
________________________________
(1)The Company reclassified rebates and allowances of $3.5 million and $8.2 million within each product category, which included $3.2 million and $7.5 million for DEFINITY, $0.3 million and $0.6 million for TechneLite and zero and $0.1 million for other precision diagnostics, for the three and six months ended June 30, 2020, respectively.
The Company’s performance obligations are typically part of contracts that have an original expected duration of one year or less. As such, the Company is not disclosing the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied (or partially satisfied) as of the end of the reporting period.